Targeted bone marrow radiation tested for myeloma relapse – trial halted early

NCT ID NCT01794572

Terminated Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a combination of high-dose chemotherapy (melphalan) and escalating doses of total bone marrow irradiation, followed by a stem cell rescue, in 13 people with multiple myeloma that had returned after initial treatment. The goal was to find the highest safe radiation dose. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Total bone marrow irradiation and melphalan chemotherapy
What this could lead to: If successful, this approach could offer a more targeted way to deliver high-dose therapy before a stem cell transplant for relapsed multiple myeloma.
What could go wrong: This was a very early, small trial that was terminated before completion. The combination of high-dose radiation and chemotherapy carries significant risks, including severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pathologic Complete Response plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA IN RELAPSE

Contacts and locations

Locations

CHU Claude Huriez, service d'hématologie

Lille, 59037, France
CHU Haut-Leveque, service d'Hématologie

Bordeaux, 33604, France
CHU Hautepierre, service d'hématologie

Strasbourg, 67098, France
CHU Hotel-Dieu, service d'hématologie

Nantes, 44093, France
CLCC Bergonie, service de radiotherapie

Bordeaux, 33076, France
CLCC ICO, service de radiothérapie

Saint-Herblain, 44805, France
CLCC Oscar Lambret, service de radiothérapie

Lille, 59020, France
CLCC Paul Strauss, service de radiothérapie

Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.